<?xml version='1.0' encoding='utf-8'?>
<document id="28336578"><sentence text="Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions." /><sentence text="Typically, concentration-response curves are based upon nominal inducer concentrations for in-vitro-to-in-vivo extrapolation of CYP3A4 induction" /><sentence text=" The limitation of this practice is that it assumes the hepatocyte culture model is a static system" /><sentence text=" We assessed whether correcting for: 1) changes in perpetrator concentration in the induction medium during the incubation period, 2) perpetrator binding to proteins in the induction medium, and 3) nonspecific binding of perpetrator can improve the accuracy of CYP3A4 induction predictions" /><sentence text=" Of the seven compounds used in this evaluation, significant parent loss and nonspecific binding were observed for rifampicin (29"><entity charOffset="115-125" id="DDI-PubMed.28336578.s5.e0" text="rifampicin" /></sentence><sentence text="3-38" /><sentence text="3%), pioglitazone (64"><entity charOffset="5-17" id="DDI-PubMed.28336578.s7.e0" text="pioglitazone" /></sentence><sentence text="3-78" /><sentence text="6%), and rosiglitazone (57"><entity charOffset="9-22" id="DDI-PubMed.28336578.s9.e0" text="rosiglitazone" /></sentence><sentence text="1-75" /><sentence text="5%)" /><sentence text=" As a result, the free measured EC50 values (EC50u) of pioglitazone, rosiglitazone, and rifampicin were significantly lower than the nominal EC50 values"><entity charOffset="55-67" id="DDI-PubMed.28336578.s12.e0" text="pioglitazone" /><entity charOffset="69-82" id="DDI-PubMed.28336578.s12.e1" text="rosiglitazone" /><entity charOffset="88-98" id="DDI-PubMed.28336578.s12.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.28336578.s12.e0" e2="DDI-PubMed.28336578.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28336578.s12.e0" e2="DDI-PubMed.28336578.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28336578.s12.e0" e2="DDI-PubMed.28336578.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28336578.s12.e1" e2="DDI-PubMed.28336578.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28336578.s12.e1" e2="DDI-PubMed.28336578.s12.e2" /></sentence><sentence text=" In general, the accuracy of the induction predictions, using multiple static models, improved when corrections were made for measured medium concentrations, medium protein binding, and nonspecific binding of the perpetrator, as evidenced by 18-29% reductions in the root mean square error" /><sentence text=" The relative induction score model performed better than the basic static and mechanistic static models, resulting in lower prediction error and no false-positive or false-negative predictions" /><sentence text=" However, even when the EC50u value was used, the induction prediction for bosentan, which is a substrate of organic anion transporter proteins, was overpredicted by approximately 2-fold"><entity charOffset="75-83" id="DDI-PubMed.28336578.s15.e0" text="bosentan" /></sentence><sentence text=" Accounting for the ratio of unbound intracellular concentrations to unbound medium concentrations (Kpuu,in vitro) (0" /><sentence text="5-7" /><sentence text="5) and the predicted multiple-dose Kpuu,in vivo (0" /><sentence text="6) for bosentan resulted in induction predictions within 35% of the observed interaction"><entity charOffset="7-15" id="DDI-PubMed.28336578.s19.e0" text="bosentan" /></sentence><sentence text="" /></document>